메뉴 건너뛰기




Volumn 10, Issue 3, 2014, Pages 381-392

CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease

Author keywords

Alzheimer's disease; amyloid peptides; Asymptomatic; A 1 42; Cerebrospinal fluid; Combination of biomarkers; Early detection; Early diagnosis; Imaging biomarkers; Magnetic resonance imaging; Mild cognitive impairment; Neurochemical biomarkers; Positron emission tomography; Preclinical; Prodromal

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

EID: 84899495209     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.04.506     Document Type: Review
Times cited : (67)

References (133)
  • 2
    • 0037135111 scopus 로고    scopus 로고
    • The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
    • Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-6.
    • (2002) Science , vol.297 , pp. 353-356
    • Hardy, J.1    Selkoe, D.J.2
  • 3
    • 78650403081 scopus 로고    scopus 로고
    • Reimagining Alzheimer's disease-an age-based hypothesis
    • Herrup K. Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 2010;30:16755-62.
    • (2010) J Neurosci , vol.30 , pp. 16755-16762
    • Herrup, K.1
  • 4
    • 77949423619 scopus 로고    scopus 로고
    • Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
    • Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.
    • (2010) Nat Rev Neurol , vol.6 , pp. 131-144
    • Blennow, K.1    Hampel, H.2    Weiner, M.3    Zetterberg, H.4
  • 7
    • 84861814820 scopus 로고    scopus 로고
    • Clinical trial designs for testing biomarker-based personalized therapies
    • LaiTL,LavoriPW, ShihMC, SikicBI. Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials 2012;9:141-54.
    • (2012) Clin Trials , vol.9 , pp. 141-154
    • Lai, T.L.1    Lavori, P.W.2    Shih, M.C.3    Sikic, B.I.4
  • 8
    • 78751692575 scopus 로고    scopus 로고
    • Anti-Abtherapeutics inAlzheimer's disease: The need for a paradigm shift
    • GoldeTE, Schneider LS,Koo EH.Anti-Abtherapeutics inAlzheimer's disease: the need for a paradigm shift. Neuron 2011;69:203-13.
    • (2011) Neuron , vol.69 , pp. 203-213
    • Golde, T.E.1    Schneider, L.S.2    Koo, E.H.3
  • 10
    • 66749116755 scopus 로고    scopus 로고
    • Existing plaques and neuritic abnormalities in APP: PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575
    • Garcia-Alloza M, Subramanian M, Thyssen D, Borrelli LA, Fauq A, Das P, et al. Existing plaques and neuritic abnormalities in APP: PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener 2009;4:19.
    • (2009) Mol Neurodegener , vol.4 , pp. 19
    • Garcia-Alloza, M.1    Subramanian, M.2    Thyssen, D.3    Borrelli, L.A.4    Fauq, A.5    Das, P.6
  • 11
    • 0036257424 scopus 로고    scopus 로고
    • The challenges of developing and validating molecular and biochemical markers of Alzheimer's disease
    • Khachaturian ZS. The challenges of developing and validating molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging 2002;23:509-11.
    • (2002) Neurobiol Aging , vol.23 , pp. 509-511
    • Khachaturian, Z.S.1
  • 16
    • 0021271971 scopus 로고
    • Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
    • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
    • (1984) Neurology , vol.34 , pp. 939-944
    • McKhann, G.1    Drachman, D.2    Folstein, M.3    Katzman, R.4    Price, D.5    Stadlan, E.M.6
  • 17
    • 84863224067 scopus 로고    scopus 로고
    • Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot
    • Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 2012;8:312-36.
    • (2012) Alzheimers Dement , vol.8 , pp. 312-336
    • Hampel, H.1    Lista, S.2    Khachaturian, Z.S.3
  • 18
    • 79956098248 scopus 로고    scopus 로고
    • Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    • Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92.
    • (2011) Alzheimers Dement , vol.7 , pp. 280-292
    • Sperling, R.A.1    Aisen, P.S.2    Beckett, L.A.3    Bennett, D.A.4    Craft, S.5    Fagan, A.M.6
  • 19
    • 79956084514 scopus 로고    scopus 로고
    • The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    • Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
    • (2011) Alzheimers Dement , vol.7 , pp. 270-279
    • Albert, M.S.1    Dekosky, S.T.2    Dickson, D.3    Dubois, B.4    Feldman, H.H.5    Fox, N.C.6
  • 20
    • 79956142378 scopus 로고    scopus 로고
    • The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    • McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9.
    • (2011) Alzheimers Dement , vol.7 , pp. 263-269
    • McKhann, G.M.1    Knopman, D.S.2    Chertkow, H.3    Hyman, B.T.4    Jack Jr., C.R.5    Kawas, C.H.6
  • 21
    • 79956090031 scopus 로고    scopus 로고
    • Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines forAlzheimer's disease
    • Khachaturian ZS. Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines forAlzheimer's disease. AlzheimersDement 2011;7:253-6.
    • (2011) AlzheimersDement , vol.7 , pp. 253-256
    • Khachaturian, Z.S.1
  • 22
    • 33747386501 scopus 로고    scopus 로고
    • Diagnosis of Alzheimer's disease: Two-decades of progress
    • Khachaturian ZS. Diagnosis of Alzheimer's disease: two-decades of progress. J Alzheimers Dis 2006;9:409-15.
    • (2006) J Alzheimers Dis , vol.9 , pp. 409-415
    • Khachaturian, Z.S.1
  • 23
    • 42049121409 scopus 로고    scopus 로고
    • Amyloid-related biomarkers for Alzheimer's disease
    • Andreasen N, Zetterberg H. Amyloid-related biomarkers for Alzheimer's disease. Curr Med Chem 2008;15:766-71.
    • (2008) Curr Med Chem , vol.15 , pp. 766-771
    • Andreasen, N.1    Zetterberg, H.2
  • 24
    • 79952793175 scopus 로고    scopus 로고
    • Amyloid b (Ab) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease
    • Prvulovic D, Hampel H. Amyloid b (Ab) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin Chem Lab Med 2011;49:367-74.
    • (2011) Clin Chem Lab Med , vol.49 , pp. 367-374
    • Prvulovic, D.1    Hampel, H.2
  • 25
    • 66149084048 scopus 로고    scopus 로고
    • Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
    • Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106:6820-5.
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 6820-6825
    • Reiman, E.M.1    Chen, K.2    Liu, X.3    Bandy, D.4    Yu, M.5    Lee, W.6
  • 26
    • 67349270965 scopus 로고    scopus 로고
    • Apolipoprotein e and its receptors in Alzheimer's disease: Pathways, pathogenesis and therapy
    • Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10:333-44.
    • (2009) Nat Rev Neurosci , vol.10 , pp. 333-344
    • Bu, G.1
  • 27
    • 34047272692 scopus 로고    scopus 로고
    • A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease
    • Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 2007;68:613-8.
    • (2007) J Clin Psychiatry , vol.68 , pp. 613-618
    • Coon, K.D.1    Myers, A.J.2    Craig, D.W.3    Webster, J.A.4    Pearson, J.V.5    Lince, D.H.6
  • 28
    • 0027407565 scopus 로고
    • Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
    • Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:1977-81.
    • (1993) Proc Natl Acad Sci U S A , vol.90 , pp. 1977-1981
    • Strittmatter, W.J.1    Saunders, A.M.2    Schmechel, D.3    Pericak-Vance, M.4    Enghild, J.5    Salvesen, G.S.6
  • 29
    • 79952812955 scopus 로고    scopus 로고
    • The effect of apolipoprotein e (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease
    • Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin Chem Lab Med 2011;49:375-83.
    • (2011) Clin Chem Lab Med , vol.49 , pp. 375-383
    • Leoni, V.1
  • 30
    • 52449089987 scopus 로고    scopus 로고
    • Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses
    • Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9:768-78.
    • (2008) Nat Rev Neurosci , vol.9 , pp. 768-778
    • Bertram, L.1    Tanzi, R.E.2
  • 31
    • 34248190279 scopus 로고    scopus 로고
    • Ab oligomers - A decade of discovery
    • Walsh DM, Selkoe DJ. Ab oligomers-a decade of discovery. J Neurochem 2007;101:1172-84.
    • (2007) J Neurochem , vol.101 , pp. 1172-1184
    • Walsh, D.M.1    Selkoe, D.J.2
  • 33
    • 77952870556 scopus 로고    scopus 로고
    • Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients
    • Zetterberg H, Tullhog K, Hansson O, Minthon L, Londos E, Blennow K. Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. Eur Neurol 2010; 63:326-30.
    • (2010) Eur Neurol , vol.63 , pp. 326-330
    • Zetterberg, H.1    Tullhog, K.2    Hansson, O.3    Minthon, L.4    Londos, E.5    Blennow, K.6
  • 34
  • 35
    • 77952542382 scopus 로고    scopus 로고
    • Biological markers of amyloid beta-related mechanisms in Alzheimer's disease
    • Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 2010;223:334-46.
    • (2010) Exp Neurol , vol.223 , pp. 334-346
    • Hampel, H.1    Shen, Y.2    Walsh, D.M.3    Aisen, P.4    Shaw, L.M.5    Zetterberg, H.6
  • 36
    • 71849099881 scopus 로고    scopus 로고
    • Amyloid beta and APP as biomarkers for Alzheimer's disease
    • Zetterberg H, Blennow K, Hanse E. Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol 2010;45:23-9.
    • (2010) Exp Gerontol , vol.45 , pp. 23-29
    • Zetterberg, H.1    Blennow, K.2    Hanse, E.3
  • 37
    • 7444253126 scopus 로고    scopus 로고
    • Cerebrospinal fluid protein biomarkers for Alzheimer's disease
    • Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004;1:213-25.
    • (2004) NeuroRx , vol.1 , pp. 213-225
    • Blennow, K.1
  • 39
    • 77955761176 scopus 로고    scopus 로고
    • Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?
    • Mitchell AJ, Monge-Argiles JA, Sanchez-Paya J. Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia? Pract Neurol 2010;10:202-7.
    • (2010) Pract Neurol , vol.10 , pp. 202-207
    • Mitchell, A.J.1    Monge-Argiles, J.A.2    Sanchez-Paya, J.3
  • 41
    • 84869126018 scopus 로고    scopus 로고
    • Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study
    • Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez- Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012;11:1048-56.
    • (2012) Lancet Neurol , vol.11 , pp. 1048-1056
    • Reiman, E.M.1    Quiroz, Y.T.2    Fleisher, A.S.3    Chen, K.4    Velez-Pardo, C.5    Jimenez- Del-Rio, M.6
  • 44
    • 59849101898 scopus 로고    scopus 로고
    • CSF amyloid-b 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction
    • Bibl M, Lewczuk P, Esselmann H, Mollenhauer B, Klafki HW, Welge V, et al. CSF amyloid-b 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction. Proteomics Clin Appl 2008;2:1548-56.
    • (2008) Proteomics Clin Appl , vol.2 , pp. 1548-1556
    • Bibl, M.1    Lewczuk, P.2    Esselmann, H.3    Mollenhauer, B.4    Klafki, H.W.5    Welge, V.6
  • 45
    • 84863423724 scopus 로고    scopus 로고
    • Cerebrospinal fluid amyloid-b 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia
    • Bibl M, Gallus M, Welge V, Esselmann H, Wolf S, Ruther E, et al. Cerebrospinal fluid amyloid-b 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J Neural Transm 2012; 119:805-13.
    • (2012) J Neural Transm , vol.119 , pp. 805-813
    • Bibl, M.1    Gallus, M.2    Welge, V.3    Esselmann, H.4    Wolf, S.5    Ruther, E.6
  • 46
    • 0037465449 scopus 로고    scopus 로고
    • CSFAb42 levels correlate with amyloid-neuropathology in a population-based autopsy study
    • Strozyk D, Blennow K, White LR, Launer LJ. CSFAb42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652-6.
    • (2003) Neurology , vol.60 , pp. 652-656
    • Strozyk, D.1    Blennow, K.2    White, L.R.3    Launer, L.J.4
  • 47
    • 33644832047 scopus 로고    scopus 로고
    • Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans
    • Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans. Ann Neurol 2006;59:512-9.
    • (2006) Ann Neurol , vol.59 , pp. 512-519
    • Fagan, A.M.1    Mintun, M.A.2    Mach, R.H.3    Lee, S.Y.4    Dence, C.S.5    Shah, A.R.6
  • 49
    • 62449262536 scopus 로고    scopus 로고
    • Cerebrospinal fluid b-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain
    • Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid b-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-9.
    • (2009) Arch Neurol , vol.66 , pp. 382-389
    • Tapiola, T.1    Alafuzoff, I.2    Herukka, S.K.3    Parkkinen, L.4    Hartikainen, P.5    Soininen, H.6
  • 51
    • 0042845853 scopus 로고    scopus 로고
    • Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    • Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, et al. Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 2003;54:263-7.
    • (2003) Ann Neurol , vol.54 , pp. 263-267
    • Wiltfang, J.1    Esselmann, H.2    Smirnov, A.3    Bibl, M.4    Cepek, L.5    Steinacker, P.6
  • 52
    • 0036182732 scopus 로고    scopus 로고
    • Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms
    • Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H, et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 2002;13:112-8.
    • (2002) Dement Geriatr Cogn Disord , vol.13 , pp. 112-118
    • Sjogren, M.1    Davidsson, P.2    Wallin, A.3    Granerus, A.K.4    Grundstrom, E.5    Askmark, H.6
  • 53
    • 0037295255 scopus 로고    scopus 로고
    • Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy
    • Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003;18:186-90.
    • (2003) Mov Disord , vol.18 , pp. 186-190
    • Holmberg, B.1    Johnels, B.2    Blennow, K.3    Rosengren, L.4
  • 56
    • 21844448609 scopus 로고    scopus 로고
    • Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay
    • Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, et al. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 2005; 58:147-50.
    • (2005) Ann Neurol , vol.58 , pp. 147-150
    • Stenh, C.1    Englund, H.2    Lord, A.3    Johansson, A.S.4    Almeida, C.G.5    Gellerfors, P.6
  • 57
    • 34250854262 scopus 로고    scopus 로고
    • Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid betachaperone in human cerebrospinal fluid
    • Kanekiyo T, Ban T, Aritake K, Huang ZL, Qu WM, Okazaki I, et al. Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid betachaperone in human cerebrospinal fluid. Proc Natl Acad Sci U S A 2007;104:6412-7.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 6412-6417
    • Kanekiyo, T.1    Ban, T.2    Aritake, K.3    Huang, Z.L.4    Qu, W.M.5    Okazaki, I.6
  • 58
    • 2942737051 scopus 로고    scopus 로고
    • Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation
    • Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, et al. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 2004;25:1033-43.
    • (2004) Neurobiol Aging , vol.25 , pp. 1033-1043
    • Sastre, M.1    Calero, M.2    Pawlik, M.3    Mathews, P.M.4    Kumar, A.5    Danilov, V.6
  • 59
    • 34250819839 scopus 로고    scopus 로고
    • Intracellular amyloid-beta in Alzheimer's disease
    • LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007;8:499-509.
    • (2007) Nat Rev Neurosci , vol.8 , pp. 499-509
    • Laferla, F.M.1    Green, K.N.2    Oddo, S.3
  • 61
    • 34247384609 scopus 로고    scopus 로고
    • Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment
    • Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:316-20.
    • (2007) Dement Geriatr Cogn Disord , vol.23 , pp. 316-320
    • Hansson, O.1    Zetterberg, H.2    Buchhave, P.3    Andreasson, U.4    Londos, E.5    Minthon, L.6
  • 62
    • 67651204382 scopus 로고    scopus 로고
    • CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment
    • Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA2009;302:385-93.
    • (2009) JAMA , vol.302 , pp. 385-393
    • Mattsson, N.1    Zetterberg, H.2    Hansson, O.3    Andreasen, N.4    Parnetti, L.5    Jonsson, M.6
  • 63
    • 32544435900 scopus 로고    scopus 로고
    • Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow- up study
    • Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow- up study. Lancet Neurol 2006;5:228-34.
    • (2006) Lancet Neurol , vol.5 , pp. 228-234
    • Hansson, O.1    Zetterberg, H.2    Buchhave, P.3    Londos, E.4    Blennow, K.5    Minthon, L.6
  • 64
    • 16844382811 scopus 로고    scopus 로고
    • CSFAbeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment
    • Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSFAbeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005;64:1294-7.
    • (2005) Neurology , vol.64 , pp. 1294-1297
    • Herukka, S.K.1    Hallikainen, M.2    Soininen, H.3    Pirttila, T.4
  • 65
    • 3142743789 scopus 로고    scopus 로고
    • Value of CSF beta-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment
    • Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705-10.
    • (2004) Mol Psychiatry , vol.9 , pp. 705-710
    • Hampel, H.1    Teipel, S.J.2    Fuchsberger, T.3    Andreasen, N.4    Wiltfang, J.5    Otto, M.6
  • 66
    • 78650413213 scopus 로고    scopus 로고
    • Diagnosis and biomarkers of predementia in Alzheimer's disease
    • Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med 2010;8:89.
    • (2010) BMC Med , vol.8 , pp. 89
    • Forlenza, O.V.1    Diniz, B.S.2    Gattaz, W.F.3
  • 67
    • 18444393054 scopus 로고    scopus 로고
    • Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation
    • Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481-96.
    • (2002) J Neurochem , vol.81 , pp. 481-496
    • Wiltfang, J.1    Esselmann, H.2    Bibl, M.3    Smirnov, A.4    Otto, M.5    Paul, S.6
  • 68
    • 82355170154 scopus 로고    scopus 로고
    • Protein profiling of cerebrospinal fluid
    • Simonsen AH. Protein profiling of cerebrospinal fluid. Methods Mol Biol 2012;818:109-17.
    • (2012) Methods Mol Biol , vol.818 , pp. 109-117
    • Simonsen, A.H.1
  • 69
    • 0038268072 scopus 로고    scopus 로고
    • The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: Evidence of a novel carboxyterminally elongated Abeta peptide
    • Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, et al. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 2003;17:1291-6.
    • (2003) Rapid Commun Mass Spectrom , vol.17 , pp. 1291-1296
    • Lewczuk, P.1    Esselmann, H.2    Meyer, M.3    Wollscheid, V.4    Neumann, M.5    Otto, M.6
  • 70
    • 12444337654 scopus 로고    scopus 로고
    • Truncated beta-amyloid peptide species in preclinical Alzheimer's disease as new targets for the vaccination approach
    • Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, et al. Truncated beta-amyloid peptide species in preclinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 2003;85:1581-91.
    • (2003) J Neurochem , vol.85 , pp. 1581-1591
    • Sergeant, N.1    Bombois, S.2    Ghestem, A.3    Drobecq, H.4    Kostanjevecki, V.5    Missiaen, C.6
  • 71
    • 24144443470 scopus 로고    scopus 로고
    • Amino-truncated {beta}-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment
    • Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, et al. Amino-truncated {beta}-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 2005;51:1650-60.
    • (2005) Clin Chem , vol.51 , pp. 1650-1660
    • Vanderstichele, H.1    De Meyer, G.2    Andreasen, N.3    Kostanjevecki, V.4    Wallin, A.5    Olsson, A.6
  • 72
    • 33645775230 scopus 로고    scopus 로고
    • Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry
    • Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 2006;5:1010-6.
    • (2006) J Proteome Res , vol.5 , pp. 1010-1016
    • Portelius, E.1    Westman-Brinkmalm, A.2    Zetterberg, H.3    Blennow, K.4
  • 74
    • 36348970121 scopus 로고    scopus 로고
    • Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry
    • Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 2007;6:4433-9.
    • (2007) J Proteome Res , vol.6 , pp. 4433-4439
    • Portelius, E.1    Tran, A.J.2    Andreasson, U.3    Persson, R.4    Brinkmalm, G.5    Zetterberg, H.6
  • 75
    • 77951718059 scopus 로고    scopus 로고
    • Optimization protocol for amyloid-b peptides detection in human cerebrospinal fluid using SELDI TOF MS
    • Albertini V, Bruno A, Paterlini A, Lista S, Benussi L, Cereda C, et al. Optimization protocol for amyloid-b peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics Clin Appl 2010; 4:352-7.
    • (2010) Proteomics Clin Appl , vol.4 , pp. 352-357
    • Albertini, V.1    Bruno, A.2    Paterlini, A.3    Lista, S.4    Benussi, L.5    Cereda, C.6
  • 78
    • 84860215636 scopus 로고    scopus 로고
    • Evaluation of the performance of novel Ab isoforms as theragnostic markers in Alzheimer's disease: From the cell to the patient
    • Portelius E, Gustavsson MK, Zetterberg H, Andreasson U, Blennow K. Evaluation of the performance of novel Ab isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient. Neurodegener Dis 2012;10:138-40.
    • (2012) Neurodegener Dis , vol.10 , pp. 138-140
    • Portelius, E.1    Gustavsson, M.K.2    Zetterberg, H.3    Andreasson, U.4    Blennow, K.5
  • 79
    • 77957257809 scopus 로고    scopus 로고
    • Acute effect on the Ab isoform pattern in CSF in response to g-secretase modulator and inhibitor treatment in dogs
    • Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, et al. Acute effect on the Ab isoform pattern in CSF in response to g-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 2010;21:1005-12.
    • (2010) J Alzheimers Dis , vol.21 , pp. 1005-1012
    • Portelius, E.1    Van Broeck, B.2    Andreasson, U.3    Gustavsson, M.K.4    Mercken, M.5    Zetterberg, H.6
  • 82
    • 68949192793 scopus 로고    scopus 로고
    • Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI)
    • Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, et al. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 2009;44:579-85.
    • (2009) Exp Gerontol , vol.44 , pp. 579-585
    • Buerger, K.1    Frisoni, G.2    Uspenskaya, O.3    Ewers, M.4    Zetterberg, H.5    Geroldi, C.6
  • 83
    • 75149128305 scopus 로고    scopus 로고
    • Alzheimer's disease and CSF biomarkers: Key challenges for broad clinical applications
    • Mattsson N, Zetterberg H. Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. Biomark Med 2009; 3:735-7.
    • (2009) Biomark Med , vol.3 , pp. 735-737
    • Mattsson, N.1    Zetterberg, H.2
  • 85
    • 84873681445 scopus 로고    scopus 로고
    • A selected reaction monitoring (SRM)-based method for absolute quantification of Ab38, Ab40, and Ab42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls
    • Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Ab38, Ab40, and Ab42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J Alzheimers Dis 2013;33:1021-32.
    • (2013) J Alzheimers Dis , vol.33 , pp. 1021-1032
    • Pannee, J.1    Portelius, E.2    Oppermann, M.3    Atkins, A.4    Hornshaw, M.5    Zegers, I.6
  • 86
    • 67650149563 scopus 로고    scopus 로고
    • Future screening for incipient Alzheimer's disease - The influence of prevalence on test performance
    • Mattsson N, Zetterberg H. Future screening for incipient Alzheimer's disease-the influence of prevalence on test performance. Eur Neurol 2009;62:200-3.
    • (2009) Eur Neurol , vol.62 , pp. 200-203
    • Mattsson, N.1    Zetterberg, H.2
  • 87
    • 79960942624 scopus 로고    scopus 로고
    • Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia
    • Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 2011;34:430-42.
    • (2011) Trends Neurosci , vol.34 , pp. 430-442
    • Ewers, M.1    Sperling, R.A.2    Klunk, W.E.3    Weiner, M.W.4    Hampel, H.5
  • 88
    • 44649165640 scopus 로고    scopus 로고
    • Diffusion spectrum magnetic resonance imaging (DSI) tractography of crossing fibers
    • Wedeen VJ,Wang RP, Schmahmann JD, Benner T, TsengWY, Dai G, et al. Diffusion spectrum magnetic resonance imaging (DSI) tractography of crossing fibers. Neuroimage 2008;41:1267-77.
    • (2008) Neuroimage , vol.41 , pp. 1267-1277
    • Wedeen, V.J.1    Wang, R.P.2    Schmahmann, J.D.3    Benner, T.4    Tseng, W.Y.5    Dai, G.6
  • 89
    • 79960619279 scopus 로고    scopus 로고
    • White matter characterization with diffusional kurtosis imaging
    • Fieremans E, Jensen JH, Helpern JA. White matter characterization with diffusional kurtosis imaging. Neuroimage 2011;58:177-88.
    • (2011) Neuroimage , vol.58 , pp. 177-188
    • Fieremans, E.1    Jensen, J.H.2    Helpern, J.A.3
  • 91
    • 84872093221 scopus 로고    scopus 로고
    • Alterations in cerebral microstructural integrity in normal aging and in Alzheimer's disease: A multi-contrast diffusion MRI study
    • Seattle, WA
    • Lu H, Jensen JH, Hu C, Falangola MF, Ramani A, Ferris S, et al. Alterations in cerebral microstructural integrity in normal aging and in Alzheimer's disease: a multi-contrast diffusion MRI study. Presented at the 14th Scientific Meeting of the ISMRM, Seattle, WA, 2006. p. 723.
    • (2006) Presented at the 14th Scientific Meeting of the ISMRM , pp. 723
    • Lu, H.1    Jensen, J.H.2    Hu, C.3    Falangola, M.F.4    Ramani, A.5    Ferris, S.6
  • 92
    • 84862502734 scopus 로고    scopus 로고
    • Alzheimer disease: New concepts on its neurobiology and the clinical role imaging will play
    • Jack CR Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 2012;263:344-61.
    • (2012) Radiology , vol.263 , pp. 344-361
    • Jack Jr., C.R.1
  • 93
    • 84864944776 scopus 로고    scopus 로고
    • CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects
    • Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JQ, Aisen P, et al. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex 2012;22:1993-2004.
    • (2012) Cereb Cortex , vol.22 , pp. 1993-2004
    • Ewers, M.1    Insel, P.2    Jagust, W.J.3    Shaw, L.4    Trojanowski, J.Q.5    Aisen, P.6
  • 96
    • 67349227896 scopus 로고    scopus 로고
    • B amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid
    • Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, et al. b amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiat 2009;65:927-34.
    • (2009) Biol Psychiat , vol.65 , pp. 927-934
    • Grimmer, T.1    Riemenschneider, M.2    Forstl, H.3    Henriksen, G.4    Klunk, W.E.5    Mathis, C.A.6
  • 98
    • 84861198255 scopus 로고    scopus 로고
    • Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance
    • Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012; 33:1203-14.
    • (2012) Neurobiol Aging , vol.33 , pp. 1203-1214
    • Ewers, M.1    Walsh, C.2    Trojanowski, J.Q.3    Shaw, L.M.4    Petersen, R.C.5    Jack Jr., C.R.6
  • 99
    • 79960638062 scopus 로고    scopus 로고
    • Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors
    • Cui Y, Liu B, Luo S, Zhen X, Fan M, Liu T, et al. Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS One 2011;6:e21896.
    • (2011) PLoS One , vol.6
    • Cui, Y.1    Liu, B.2    Luo, S.3    Zhen, X.4    Fan, M.5    Liu, T.6
  • 101
    • 68249111164 scopus 로고    scopus 로고
    • MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change
    • Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 73:294-301.
    • (2009) Neurology , vol.73 , pp. 294-301
    • Vemuri, P.1    Wiste, H.J.2    Weigand, S.D.3    Shaw, L.M.4    Trojanowski, J.Q.5    Weiner, M.W.6
  • 102
    • 84859394188 scopus 로고    scopus 로고
    • Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment
    • Schmand B, Eikelenboom P, van Gool WA. Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. J Alzheimers Dis 2012;29:641-8.
    • (2012) J Alzheimers Dis , vol.29 , pp. 641-648
    • Schmand, B.1    Eikelenboom, P.2    Van Gool, W.A.3
  • 103
    • 80054765270 scopus 로고    scopus 로고
    • Alzheimer's Disease Neuroimaging Initiative. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts
    • Schmand B, Eikelenboom P, van Gool WA. Alzheimer's Disease Neuroimaging Initiative. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts. J Am Geriatr Soc 2011;59:1705-10.
    • (2011) J Am Geriatr Soc , vol.59 , pp. 1705-1710
    • Schmand, B.1    Eikelenboom, P.2    Van Gool, W.A.3
  • 104
    • 84864383552 scopus 로고    scopus 로고
    • Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI
    • Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 2012;33:2272-81.
    • (2012) Neurobiol Aging , vol.33 , pp. 2272-2281
    • Vos, S.1    Van Rossum, I.2    Burns, L.3    Knol, D.4    Scheltens, P.5    Soininen, H.6
  • 109
    • 60349119623 scopus 로고    scopus 로고
    • Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease
    • Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, et al. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis 2009;16:351-62.
    • (2009) J Alzheimers Dis , vol.16 , pp. 351-362
    • Brys, M.1    Glodzik, L.2    Mosconi, L.3    Switalski, R.4    De Santi, S.5    Pirraglia, E.6
  • 110
    • 54149086289 scopus 로고    scopus 로고
    • Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease
    • Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, et al. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry 2008;64:871-9.
    • (2008) Biol Psychiatry , vol.64 , pp. 871-879
    • Devanand, D.P.1    Liu, X.2    Tabert, M.H.3    Pradhaban, G.4    Cuasay, K.5    Bell, K.6
  • 111
    • 34249871381 scopus 로고    scopus 로고
    • FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment
    • Fellgiebel A, Scheurich A, Bartenstein P, Muller MJ. FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res 2007;155:167-71.
    • (2007) Psychiatry Res , vol.155 , pp. 167-171
    • Fellgiebel, A.1    Scheurich, A.2    Bartenstein, P.3    Muller, M.J.4
  • 112
    • 57749091995 scopus 로고    scopus 로고
    • Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease
    • Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2009;30:165-73.
    • (2009) Neurobiol Aging , vol.30 , pp. 165-173
    • Hansson, O.1    Buchhave, P.2    Zetterberg, H.3    Blennow, K.4    Minthon, L.5    Warkentin, S.6
  • 113
    • 77954032616 scopus 로고    scopus 로고
    • Boosting power for clinical trials using classifiers based on multiple biomarkers
    • Kohannim O, Hua X, Hibar DP, Lee S, Chou YY, Toga AW, et al. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging 2010;31:1429-42.
    • (2010) Neurobiol Aging , vol.31 , pp. 1429-1442
    • Kohannim, O.1    Hua, X.2    Hibar, D.P.3    Lee, S.4    Chou, Y.Y.5    Toga, A.W.6
  • 114
    • 84861645859 scopus 로고    scopus 로고
    • Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion
    • Westman E, Muehlboeck JS, Simmons A. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Neuroimage 2012; 62:229-38.
    • (2012) Neuroimage , vol.62 , pp. 229-238
    • Westman, E.1    Muehlboeck, J.S.2    Simmons, A.3
  • 115
    • 65249092480 scopus 로고    scopus 로고
    • Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers
    • Hampel H, Broich K. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers. J Nutr Health Aging 2009;13:373-5.
    • (2009) J Nutr Health Aging , vol.13 , pp. 373-375
    • Hampel, H.1    Broich, K.2
  • 117
    • 69249231987 scopus 로고    scopus 로고
    • Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects
    • Hua X, Lee S, Yanovsky I, Leow AD, Chou YY, Ho AJ, et al. Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage 2009;48:668-81.
    • (2009) Neuroimage , vol.48 , pp. 668-681
    • Hua, X.1    Lee, S.2    Yanovsky, I.3    Leow, A.D.4    Chou, Y.Y.5    Ho, A.J.6
  • 118
    • 84867502641 scopus 로고    scopus 로고
    • Enriching amnestic mild cognitive impairment populations for clinical trials: Optimal combination of biomarkers to predict conversion to dementia
    • Yu P, Dean RA, Hall SD, Qi Y, Sethuraman G, Willis BA, et al. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. J Alzheimers Dis 2012;32:373-85.
    • (2012) J Alzheimers Dis , vol.32 , pp. 373-385
    • Yu, P.1    Dean, R.A.2    Hall, S.D.3    Qi, Y.4    Sethuraman, G.5    Willis, B.A.6
  • 119
    • 37349026227 scopus 로고    scopus 로고
    • Multicenter assessment of CSFphosphorylated tau for the prediction of conversion of MCI
    • Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, et al. Multicenter assessment of CSFphosphorylated tau for the prediction of conversion of MCI. Neurology 2007;69:2205-12.
    • (2007) Neurology , vol.69 , pp. 2205-2212
    • Ewers, M.1    Buerger, K.2    Teipel, S.J.3    Scheltens, P.4    Schroder, J.5    Zinkowski, R.P.6
  • 121
  • 123
    • 77954033765 scopus 로고    scopus 로고
    • Alzheimer's disease neuroimaging initiative in Europe
    • Frisoni GB. Alzheimer's disease neuroimaging initiative in Europe. Alzheimers Dement 2010;6:280-5.
    • (2010) Alzheimers Dement , vol.6 , pp. 280-285
    • Frisoni, G.B.1
  • 125
    • 82755187525 scopus 로고    scopus 로고
    • Ethical considerations of biomarker use in neurodegenerative diseases - A case study of Alzheimer's disease
    • Prvulovic D, Hampel H. Ethical considerations of biomarker use in neurodegenerative diseases-a case study of Alzheimer's disease. Prog Neurobiol 2011;95:517-9.
    • (2011) Prog Neurobiol , vol.95 , pp. 517-519
    • Prvulovic, D.1    Hampel, H.2
  • 126
    • 82755197883 scopus 로고    scopus 로고
    • Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention
    • Trojanowski JQ, Hampel H. Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. Prog Neurobiol 2011;95:491-5.
    • (2011) Prog Neurobiol , vol.95 , pp. 491-495
    • Trojanowski, J.Q.1    Hampel, H.2
  • 127
    • 82755182821 scopus 로고    scopus 로고
    • Perspectives of worldwide translational biomarker research in neurodegenerative diseases
    • Nicotera P, Hampel H. Perspectives of worldwide translational biomarker research in neurodegenerative diseases. Prog Neurobiol 2011;95:496-7.
    • (2011) Prog Neurobiol , vol.95 , pp. 496-497
    • Nicotera, P.1    Hampel, H.2
  • 128
    • 82755197084 scopus 로고    scopus 로고
    • The role of genetics for biomarker development in neurodegeneration
    • Bertram L, Hampel H. The role of genetics for biomarker development in neurodegeneration. Prog Neurobiol 2011;95:501-4.
    • (2011) Prog Neurobiol , vol.95 , pp. 501-504
    • Bertram, L.1    Hampel, H.2
  • 129
    • 84868582421 scopus 로고    scopus 로고
    • Alzheimer disease: From inherited to sporadic AD-crossing the biomarker bridge
    • Hampel H, Lista S. Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. Nat Rev Neurol 2012;8:598-600.
    • (2012) Nat Rev Neurol , vol.8 , pp. 598-600
    • Hampel, H.1    Lista, S.2
  • 130
    • 67649628753 scopus 로고    scopus 로고
    • Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study
    • Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund- Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009;8:619-27.
    • (2009) Lancet Neurol , vol.8 , pp. 619-627
    • Visser, P.J.1    Verhey, F.2    Knol, D.L.3    Scheltens, P.4    Wahlund, L.O.5    Freund- Levi, Y.6
  • 131
    • 84867886105 scopus 로고    scopus 로고
    • Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease
    • Visser PJ, Vos S, van Rossum I, Scheltens P. Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. Alzheimers Dement 2012;8:560-3.
    • (2012) Alzheimers Dement , vol.8 , pp. 560-563
    • Visser, P.J.1    Vos, S.2    Van Rossum, I.3    Scheltens, P.4
  • 132
    • 84865085141 scopus 로고    scopus 로고
    • Alzheimer's disease diagnostic criteria: Practical applications
    • Cummings J. Alzheimer's disease diagnostic criteria: practical applications. Alzheimers Res Ther 2012;4:35.
    • (2012) Alzheimers Res Ther , vol.4 , pp. 35
    • Cummings, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.